Fundraising FoxLumabs
1 known investors
Find your way into Lumabs
LUMABS BV develops RAPPID, a rapid, one-step immunoassay technology that enables sensitive antibody detection from minimal blood samples for diagnostics and therapeutic monitoring. The company serves immunoassay diagnostic companies, clinical laboratories, biotech organizations, and research groups seeking faster, more sensitive alternatives to traditional ELISA-based assays.
Investors · 1
NLClisted by NLCAmsterdam
How we know: NLC's portfolio page · Not right? Tell us
Frequently asked questions
- What does Lumabs do?
- LUMABS BV develops RAPPID, a rapid, one-step immunoassay technology that enables sensitive antibody detection from minimal blood samples for diagnostics and therapeutic monitoring. The company serves immunoassay diagnostic companies, clinical laboratories, biotech organizations, and research groups seeking faster, more sensitive alternatives to traditional ELISA-based assays.
- Who are Lumabs's investors?
- Lumabs's investors include NLC.